Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts. On October 30, 2023, Gelesis Holdings, Inc., along its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Metrics to compare | GLSHQ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGLSHQPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −2.9x | −0.6x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price / Book | 0.0x | 1.6x | 2.6x | |
Price / LTM Sales | 0.0x | 18.6x | 3.2x | |
Upside (Analyst Target) | 0.0% | 225.4% | 48.5% | |
Fair Value Upside | Unlock | 2.4% | 7.8% | Unlock |